Login to Your Account



EUSA's Erwinaze Approval Positions Private Company for Exit

By Trista Morrison
Staff Writer

Wednesday, November 23, 2011

EUSA Pharma Inc.'s FDA approval of acute lymphoblastic leukemia (ALL) drug Erwinaze (asparaginase Erwinia chrysanthemi) means the privately held specialty pharma firm may now be poised for an exit.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription